AIMCA
CTMX icon

Alberta Investment Management Corp (AIMCo)’s CytomX Therapeutics CTMX Stock Holding History

Alberta Investment Management Corp (AIMCo)’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-20,000
Closed -$422K – 775
2017
Q4 		$422K Buy
+20,000
New +$415K ﹤0.01% 650
2017
Q3 		– Sell
-13,000
Closed -$202K – 744
2017
Q2 		$202K Buy
+13,000
New +$196K ﹤0.01% 712

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Alberta Investment Management Corp (AIMCo)'s CTMX Position: Q1 2018 in Review

Alberta Investment Management Corp (AIMCo) sold out of CytomX Therapeutics (CTMX) in Q1 2018, closing a stake of 20,000 shares — an estimated $422K sold.

Alberta Investment Management Corp (AIMCo) first reported a position in CTMX in Q2 2017 and held it in 2 quarters. The position peaked at $422K in Q4 2017. 141 funds tracked by Wall St. Rank hold CTMX as of Q1 2018.

  • Alberta Investment Management Corp (AIMCo) reported no remaining CytomX Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Alberta Investment Management Corp (AIMCo) sold 20,000 CytomX Therapeutics shares in Q1 2018, an estimated $422K.
  • Alberta Investment Management Corp (AIMCo) first reported a position in CytomX Therapeutics in Q2 2017 and held it in 2 quarters.
  • Alberta Investment Management Corp (AIMCo)'s CytomX Therapeutics position peaked at $422K in Q4 2017.
  • 141 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2018.

Based on Alberta Investment Management Corp (AIMCo)'s 13F filing for Q1 2018, filed 16 May 2018.